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Abstract
Matrix Metalloproteinase (MMP) was broadly studied as one of the protein targets in stopping 
angiogenesis. The most common target in MMP, i.e., the catalytic site, is reported as being the non-
selective target for inhibition amongst all MMPs, but its inhibition is associated with adverse side 
effects. Hemopexin in MMP9 (PEX9) was found to be different to the other domains in the MMP 
family, which could be the next target for anticancer due to the availability of its crystal structure in 
the protein data bank (pdb). In this study, we design the analogues of a compound from the ZINC 
database bearing a pyrimidinone scaffold which previously showed activity as a PEX9 inhibitor using 
molecular docking. The docking is carried out using Autodock 4.0 with parameters such as 250 run 
and lammarckian genetic algorithm. The result shows that six designed compounds have a free energy 
of binding from -7.0 to -11.0 kcal/mol. The important amino acid residues which are involved in the 
hydrogen bond interaction are ARG106, GLU60, GLU14, and GLN154. In conclusion, the six design 
compounds could give an insight mechanism to inhibit the PEX-9 activity in silico.
Keywords: Docking, Hemopexin, MMP9, PEX9, Thioguanine
Uji Aktivitas Turunan Thioguanine Terhadap Hemopexin Matrix 
Metalloproteinase9 (Pex-9) In silico
Abstrak
Matrix Metalloproteinase (MMP) telah dipelajari sebagai salah satu target protein dalam menghentikan 
angiogenesis. Catalytic site yang merupakan bagian yang banyak ditarget dari MMP dilaporkan bersifat 
tidak selektif untuk dihambat sehingga menimbulkan efek samping. Hemopexin pada MMP9 (PEX9) 
ditemukan berbeda dengan domain pada MMP lain sehingga dapat digunakan sebagai target baru untuk 
antikanker karena ketersediaan struktur kristalnya di protein data bank (pdb). Pada penelitian ini, kami 
mendesain analog senyawa dari database ZINC yang mempunyai kerangka pyrimidinone yang pada 
penelitian sebelumnya ditemukan memiliki aktivitas menghambat PEX9 dengan docking. Docking 
dilakukan dengan menggunakan Autodock 4.0 dengan parameter seperti 250 run dan algoritma genetik 
lammarckian. Hasil menunjukkan enam senyawa memiliki energi ikatan sebesar -7.0 sampai -11.0 kcal/
mol. Residu asam amino yang penting berinteraksi secara hidrogen dengan ligan antara lain ARG106, 
GLU60, GLU14, dan GLN154. Dapat disimpulkan bahwa keenam senyawa kemungkinan mempunyai 
mekanisme menghambat MMP9 pada bagian hemopexin domain in silico. 
Kata Kunci: Docking, Hemopexin, MMP9, PEX9, Tioguanin
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1. Introduction
Cancer is the second main cause of 
mortality in the world. In 2012, there were 
14.1 million new cancer cases worldwide. 
Breast cancer is the most common case in 
female.1 In 2013, breast cancer has been 
reported as one of the cancer diseases with the 
highest prevalence in Indonesia, i.e. 0,5%.2 
According to the World Health Organization 
(2014), the death caused by breast cancer in 
Indonesian female is quite high, i.e. 21.4%.3
Cancer is a complicated disease which 
is indicated by abnormal and uncontrolled 
cell growth caused by genetic mutation and 
therefore spread over from one to another 
organ. The expansion of cancer cells is 
named by metastasis which is the primary 
cause of death in cancer patients.4 Welch, 
Steeg, & Rinker-schaeffer (2000) defined that 
metastasis of cancer cells to visceral organs 
and brain has been identified to danger and 
shortens the expectation of life up to 5 years 
with the probability is less than 20%.5 Cancer 
metastasis causes death in 90% of people 
with it.6
Matrix metalloproteinases (MMPs) has 
an important rule in the invasion and metastasis 
of cancer cells. Instead, MMP also takes a role 
in angiogenesis.7 This is an enzyme belonging 
to zinc-dependent endopeptidase working by 
degrading extracellular matrix (ECM). In 
human, there are 23 MMP subfamilies which 
are categorized in to 6 types based on their 
substrate specificity.8
Studies have been reporting the function 
of MMP in breast cancer using the ELISA 
method, that the level of MMP-9 has been 
indicated at a higher concentration than normal 
breast cells. In breast cancer, MMP-9 is found 
at the stage of development and metastasis 
associated with cancer cell proliferation, 
tumor invasion and mesenchymal epithelial 
transformation.9 Overexpression of MMP-9 
is also a marker of breast cancer with triple-
negative and HER2 positive type.10
Naturally, MMP is controlled by tissue 
inhibitor for metalloproteinases (TIMP), 
however at breast cancer, the level of TIMP 
is insufficient to balance the MMPs activity.7 
Many MMP inhibitors such as marimastat, 
batimastat, periostat, etc. have been studied, 
unfortunately, none of them has successfully 
passed the third clinical trial. This is due to 
its unselective target leading to adverse side 
effect such as musculoskeletal syndrome.11 
The unselectivity is caused by a high 
homology among all MMPs particularly, in 
the catalytic domain by sharing more than 
45% homology.12 Interestingly there is one 
domain call as hemopexin which shares only 
25% homology to all others.12 Therefore 
hemopexin could be a more selective target 
than catalytic domain in the drug discovery of 
cancer by targeting MMP. 
The previous study has found MMP 
hemopexin-9 (PEX-9) inhibitor based on 
pyrimidine and arylamide scaffold with Kd 
= 2,2 μM. Pyrimidine ring provides planar 
conformation that fits the deep pocket near 
blade four at the active site of PEX-9. On 
the other hand, arylamide with a methylene 
chain facilitates flexible conformation on the 
surface of the PEX-9 active site. In this study, 
we adopt pharmacophores mimics Dufour's 
compound by modifying the pyrimidine 
ring which is changed to purine ring. The 
purine ring we utilized is thioguanine which 
also provides planar conformation as well 
as Sulphur atom at Dufour’s compound. In 
this present study, we perform computational 
study via molecular docking of thioguanine 
derivatives against the crystal structure of 
hemopexin MMP-9 (PEX-9) i.e. PDB 1ITV. 
The docking result will be analysed according 
to the energy of binding and molecular 
interactions. We hope that this study will 




ASUS Laptop with a 7th generation 
i7 intel processor, 8 GB RAM, and 1 TB 
harddisk; Discovery Studio 3.5 software; 
Autodocktools 1.5.6 software; Autodock 4.0 
software; and Marvin Sketch 16.2.15 software
2.2. Materials
Crystal structure of PEX-9 (PDB 1TV) 
downloaded from protein data bank website 





2.3.1. Validation with control docking
The crystal structure of PEX-9 (PDB 
1ITV) is downloaded from protein data 
bank (www.rcsb.com) and then uploaded 
in Discovery Studio 3.5 (www.accelerys.
com). The PEX-9 crystal structure is dimer 
therefore, one monomer is removed. The 
water is also removed and the sulphate ion 
is separated from the protein. Either protein 
or sulphate ion is saved in the pdb file. 
Both ligand and protein are prepared using 
Autodocktools 1.5.6 (www.scripps.edu) by 
adding Gasteiger and Kolmann for ligand 
and protein, respectively. The grid box is 
set to number of points 70 x 70 x 70 with 
spacing 0.375 Å and coordinate x = -42.053, 
y = -30.855 and z = -1.804. The docking is 
run using Autodock 4.0 with 250 iterations 
and lammarckian genetic algorithm. Other 
parameters use the default set in the software. 
The control docking is defined as good when 
the RMSD value toward the initial pose is less 
than 2.0 Å. 
2.3.2. Docking of thioguanine ligand
On the other hand, the 2D structure 
of ligands is sketched using Marvin Sketch 
16.2.15 and saved in mol file. The mol file 
ligands are prepared further in Discovery 
Studio 3.5 and then saved in pdb file. Both 
ligand and protein are prepared using the 
same parameters with the control docking 
above. The docking result is analysed by 
selecting the docking pose according to 
cluster, free energy of binding (ΔGbind) and 
molecular interaction with important amino 
acid residues.
3. Results
There have been six thioguanine ligands 
designed to be docked into PEX-9 binding 
site. Figure 1 illustrates the structure of the 
PEX-9 inhibitor and the thioguanine ligand 
adapted from it. The ligands have arylamide 
with a modification of diverse functional 
groups including sulphonamide, an ester of 
ethyl carboxylate, 3,4,5-trimethoxy, diazine, 
merazine, and methazine. Table 1 presents 
the result of docking based on ΔGbind and 
hydrogen bonds (H-bonds) interactions with 
important amino acid residues.
The control docking is evaluated by 
checking the RMSD value which is observed 
as 0.98 Å. The free energy of binding of 
sulphate ion is -5.0 kcal/mol. The amino acid 
residues have been observed in the molecular 
interaction with the sulphate ion is ARG10. 
Figure 2 illustrates the superposition of control 
docking pose and initial pose of sulphate ion 
into the PEX-9 binding site.
Ligand 1 has sulphonamide at the 
Figure 1. The structure of (a) PEX-9 inhibitor by Dufour et al., (2011) and (b) the thioguanine ligand 
adapted from (a) with R: (1) sulphonamide, (2) esther of ethyl carboxylate, (3) 3,4,5-trimethoxy, 
(4) diazine, (5) merazine, and (6) methazine
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p-position of arylamide possessing H-bond 
interaction with GLU14 at its N-sulphonamide, 
GLN154 at H-sulphonamide and H-imidazole 
ring, whereas the N-guanine interacts with 
GLU157. Ligand 2 bearing ester ethyl 
benzoate at its arylamide p-postion by 
exhibiting similar binding mode at GLU14 
with H-N propyl. One extra H-bond which is 
different from ligand 1 is at GLU60 interacting 
with at O-carbonyl of the ester group. Figure 3 
illustrates the molecular interactions of ligand 
1 and 2 at the binding site of PEX9. 
Ligand 3 employs 3,4,5-trimethoxy at 
the R1, R2, and R3 at the arylamide p-position 
demonstrating extremely different binding 
pose with the previous two ligands. The 
thioguanine ring which is commonly attracted 
to the site nearby GLN154 and GLU157 flips 
away from there to bind to the site surrounded 
by GLU14 and GLU60. Ligand 4 as it has 
sulphonamide attachment at its arylamide 
p-position, also has an extra pyrimidine ring 
Ligands R1 R2 R3 ∆Gbind (kcal/mol) H Bond




2 H H -10.04 GLU60, GLU14









5 H H -8.21 GLU14, ASN17
6 H H -8.83 GLU157, GLU 154, GLU14
Table 1. The result of docking based on ΔGbind and molecular interactions with important amino acid 
residues
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which gives additional H-bond interactions 
with GLY16, ASN17 and GLU157, instead of 
ARG106 and GLN154. Figure 4 illustrates the 
binding pose of ligand 3 and 4 at the binding 
site of PEX9.
Ligand 5 and 6 have a similar structure 
with ligand 4, but ligand 5 has an extra 
methyl group attached at its pyrimidine ring 
4-position. Ligand 5 has H-bond interaction 
with GLU14 and ASN17. Ligand 6 has two 
extra methyl groups attached at 4,6-position. 
Ligand 6 has H-bond interaction with 
GLU157, GLN154, and GLU14. Figure 5 
illustrates the binding pose of ligand 3 and 4 
at the binding site of PEX9.  
4. Discussion
The idea to create thioguanine as the 
ligand is inspired by the study of Dufour 
et al., (2011) and Alford et al., (2017).12,13 
Dufour reported earlier that compound 
bearing pyrimidine and arylamide connected 
by flexible ethylene chain contributes to 
the binding into PEX-9 binding site. The 
pyrimidine is reported for its binding into the 
PEX-9 due to the six-member heterocycle ring 
which provides a planar conformation that 
fits into the cavity of PEX9 domain blades. 
Besides, the arylamide moiety facilitates a 
more flexible conformation, which bound to 
the surface near to the cavity.
Figure 2. The superposition of a) control docking pose and initial pose of sulphate ion and b) the six 
thioguanine ligands into PEX-9 binding site
Figure 3. The molecular interactions of a) ligand 1 and b) 2 at the binding site of PEX9
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The parameter of docking as well as the 
quality of crystal structure are defined as valid 
because it is less than 2 Å (0,98 Å). The free 
energy of binding of sulphate ion is -5.0 kcal/
mol defining the affinity of the ligand with 
the protein. The amino acid residues have 
been observed in the molecular interaction 
with the sulphate ion is ARG10 indicating 
the importance of this amino acid residue 
in the PEX9 binding site. This describes the 
capability of the crystal structure to be used 
as the protein model to predict the new ligand 
proposed for the PEX-9 inhibitor.
Thioguanine is used for the planar ring 
as it is similar to the character of pyrimidine 
by Dufour’s hit compound. Among the six 
Figure 4. The molecular interactions of a) ligand 3 and b) 4 at the binding site of PEX9
Figure 5. The docking poses of a) ligand 5 and b) ligand 6 into the binding site of PEX-9
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ligands, the one having the lowest ΔGbind is 
ligand 1 associating with its highest capacity 
of the ligand to bind the PEX-9 binding site. 
The second lowest ∆Gbind goes to ligand 2. 
Ligand 3 attracted to the site nearby GLN154 
and GLU157 flips away from there to bind to 
the site surrounded by GLU14 and GLU60. 
These interactions contribute to the ∆Gbind 
of ligand 3 become higher than five other 
ligands. This could be affected by the different 
character of R groups being attached in 
arylamide. Methoxy group is totally electron 
donating group (EDG) which is different 
from two previous ligand, which employs 
dominantly electron withdrawing group 
(EWG). However, one of similar interaction 
with that of control docking is the interaction 
between O-carbonyl amide with ARG106 
associating with potential interaction with the 
corresponding protein. 
Ligand 4 does a similar pose with that of 
ligand 1. An extra pyrimidine ring here gives 
additional H-bond interactions with GLY16, 
ASN17 and GLU157, instead of ARG106 and 
GLN154 are assigned as important ones. The 
∆Gbind of ligand 4 is lower than ligand 3, 
however this is still higher than ligand 1 and 
2. Interestingly, the pose of thioguanine ring, 
and arylamide combined with sulphonamide 
pyrimidine is similar to that ligand 1. The 
last two ligands (5 and 6) are the extention of 
ligand 4 by attaching 4-methyl group at ligand 
5 and 4,6-dimethyl group at ligand 6. The pose 
of thioguanine ring is roughly similar where 
GLN154 and GLU157  being surrounded and 
the arylamide poses surround GLU14 and 
GLU60. The most difference between them 
is the absence of interaction with ARG106 in 
ligand 6 associating with its higher ∆Gbind 
because this kind of interaction is predicted 
to have the contribution in protein-ligand 
binding.
5. Conclusion
There have been six ligands bearing 
thioguanine as the scaffold designed as 
PEX-9 inhibitor. The thioguanine having 
planar character is expected to interact 
with a deep pocket of PEX-9 surrounded 
by GLU154 and GLN 157, whereas the 
aryamide ring connected by ethylene chain 
to the thioguanine is expected to bind to the 
shallow pocket near the surface surrounded 
by GLU14 and GLU60 of PEX-9. In addition, 
the extention of the diverse functional group 
at the p-position of the arylamide ring is aimed 
to give extra binding to the enzyme. The free 
energy of binding for all six ligands are at 
a range -11.10 to -8.21 associating with its 
capability to strongly bind to PEX-9. Further 
studies should chemically synthesize these 
six ligands to be proven its in silico prediction 
by in vitro evaluation. 
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